Expression of Bcl-2 and Bax in oligodendrogliomas and their relationship to apoptosis

Neuropathology and Applied Neurobiology

Volumn 25, Issue 5, 1999, Pages 400-407

  Delgado, M B ^a   Anderson, J R ^b   Whittle, I R ^a   Wharton, S B ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bax; Bcl 2; Oligodendroma

Indexed keywords

EOSIN; HEMATOXYLIN; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; CYTOPLASM; DNA NICK TRANSLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NERVE CELL; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; OLIGODENDROGLIOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0032725811     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1999.00199.x     Document Type: Article

References (48)

1. 1 Alvord EC. Is necrosis helpful in the grading of gliomas? Editorial Opinion. J Neuropathol Exp Neurol 1992; 51: 127-32
2. 2 Balmaceda C. Advances in brain tumor chemosensitivity. Curr Opin Oncol 1998; 10: 194-200
3. 3 Bates S, Vousden KH. P53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Devel 1996; 6: 12-9
4. 4 Benitez-Bribiesca L. Assessment of apoptosis in tumour growth: importance in clinical oncology and cancer therapy. In: When Cells Die. Eds. RA Lockshin, Z Zakeri, JL Tilly. New York: Wiley-Liss, 1998: 453-77
5. 5 Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC, Bullard DE. Clinicopathologic correlations in the oligodendroglioma. Cancer 1987; 59: 1345-52
6. 6 Cairncross JG, MacDonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360-4
7. 7 Couldwell WT, Hinton DR. Oligodendroglioma. In Brain Tumours. Chapter 26, Eds. AH Kaye, ER Laws. New York: Churchill Livingstone 1995.
8. 8 Ellison DW, Steart PV, Gatter KC, Weller RO. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995; 21: 352-61
9. 9 Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Devel 1996; 6: 45-9
10. 10 Fulci G, Ishii N, Van Meir EG. P53 and brain tumours: from gene mutations to gene therapy. Brain Pathol 1998; 8: 599-613
11. 11 Gartner A, Hengartner MO. Genetic approaches to programmed cell death in C. elegans. In: When Cells Die. Eds. RA Lockshin, Z Zakeri, JL Tilly. New York: Wiley-Liss, 1998: 131-46
12. 12 Hall PA, Meek D, Lane DP. P53 - integrating the complexity. J Pathol 1996; 180: 1-5
13. 13 Iwadate Y, Fujimoto S, Tagawa M et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1946; 69: 236-40
14. 14 Iwadate Y, Tagamwa M, Fujimoto S et al. Mutations of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer 1998; 77: 547-51
15. 15 Kaufman SH. Proteolytic cleavage during chemotherapy-induced apoptosis. Mol Med Today 1996 298-303
16. 16 Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-86
17. 17 Krajewski S, Krajewska M, Ehrmann J et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1 and Bax in tumours of central and peripheral nervous system origin. Am J Pathol 1997; 150: 805-14
18. 18 Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-20
19. 19 Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-31
20. 20 Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-90
21. 21 Mason DY, Gatter KC. Immunohistochemistry in histological diagnosis. In Recent Advances in Histopathology, Vol 16, Eds. PP Anthony, RNM Macsween. Edinburgh: Churchill Livingstone 1994: 263-92
22. 22 Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE. Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Ep Neurol 1986; 45: 65-78
23. 23 Nakagawa S, Shiraishi T, Kihara S, Tabuchi K. Detection of DNA strand breaks associated with apoptosis in human brain tumours. Virchows Arch 1995; 427: 175-9
24. 24 Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J. Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 1994; 88: 520-6
25. 25 Newcomb EW, Bhalla SK, Parrish CL. Hayes RL, Cohen H, Miller DC. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 1997; 94: 369-75
26. 26 Nunez G, Seto M, Seremetis S et al. Growth and tumour promoting effects of deregulated Bcl-2 in human B lymphoblastoid cell lines. Proc Natl Acad Sci USA 1989; 86: 4589-93
27. 27 Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EX, Kleihues P. p53 mutations in non astrocytic human brain tumours. Cancer Res 1991; 51: 6202-5
28. 28 Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerises in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19
29. 29 Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26
30. 30 Reifenberger G, Kros JM, Schiffer D, Collins VP. Oligodendroglioma and anaplastic oligodendroglioma. In Tumours of the Nervous System. Pathology and Genetics. Eds. P Kleihues, WK Cavenee. Lyon: IARC, 1997: 37-44
31. 31 Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R. Bcl-2 family protein expression in human malignant glioma: a clinico-pathological correlative study. J Neurol Sci 1998; 155: 68-75
32. 32 Schiffer D, Cavalla P, Migheli A et al. Apoptosis and cell proliferation in human neuroepithelial tumours. Neurosci Lett 1995; 195: 81-4
33. 33 Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L. Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neuro-Oncol 1996; 27: 101-9
34. 34 Schiffer D, Dutto A, Cavalla P, Chio A, Migheli A, Piva R. Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem Int 1997; 31: 245-50
35. 35 Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187: 127-37
36. 36 Sjostrom J, Krajewski S, Franssila K et al. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 1998; 78: 812-5
37. 37 Soini Y, Tormanen U, Paakko P. Apoptosis is inversely related to bcl-2 but not to bax expression in salivary gland tumours. Histopathology 1998; 32: 28-43
38. 38 Steel GG. Basic theory of growing cell populations. In Growth Kinetics of Tumours. Oxford: Clarendon Press, 1977: 57-85
39. 39 Von Wasielewski R, Mengel M, Gignac S, Wilkens L, Werner M, Georgii A. Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem 1997; 45: 1455-9
40. 40 Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6
41. 41 Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-43
42. 42 Weller M, Rieger J. Grimmel C et al. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analysis. Int J Cancer 1998; 79: 640-4
43. 43 Wharton SB, Chan KK, Hamilton FA, Anderson JR. Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study. Neuropathol Appl Neurobiol 1998; 24: 302-8
44. 44 Wharton SB, Hamilton FA, Chan WK, Chan KK, Anderson JR. Proliferation and cell death in oligodendrogliomas. Neuropathol Appl Neurobiol 1998; 24: 21-8
45. 45 Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991; 65: 1097-8
46. 46 Williams JR, Leaver HA, Ironside JW, Miller EP, Whittle IR, Gregor A. Apoptosis in human primary brain tumours: actions of arachidonic acid. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 193-200
47. 47 Wilkinson IMS, Anderson JR, Holmes AE. Oligodendroglioma: an analysis of 42 cases. J Neurol Neurosurg Psychiatry 1987; 50: 304-12
48. 48 Yin C, Knudson M, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-40